Leukapheresis not clearly linked to lower 30-day mortality in AML with hyperleukocytosisLeukapheresis Shows No Clear Early Death Benefit in AML

Expert review of hematology Published August 3, 2026 Study authors: Reyes Jamiel, Reyes Alexander PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Interpret leukapheresis cautiously in AML with hyperleukocytosis; evidence for 30-day mortality benefit is very low certainty.

This meta-analysis pooled data from 1406 adults with acute myeloid leukemia (AML) and hyperleukocytosis to evaluate the association between leukapheresis and 30-day mortality. The primary outcome was 30-day mortality, comparing leukapheresis with no leukapheresis. The pooled analysis found no clear association: the odds ratio was 0.94 (95% CI 0.65-1.34), indicating no significant difference in 30-day mortality between groups.

The authors note that most included studies were at serious risk of bias, and the certainty of evidence was very low (GRADE). Confounding by indication is a major limitation, as patients who received leukapheresis may differ systematically from those who did not, making it difficult to establish a causal benefit.

Given these limitations, the current non-randomized evidence does not establish a reliable early-mortality benefit of leukapheresis in this setting. The findings highlight the need for cautious interpretation and underscore that association does not imply causation.

For clinicians, this meta-analysis suggests that the routine use of leukapheresis for hyperleukocytosis in AML is not supported by high-quality evidence for reducing 30-day mortality. Decisions should consider individual patient factors and the overall clinical context, recognizing the uncertainty in the evidence base.

How this fits prior evidence

This meta-analysis extends prior coverage on AML management by addressing a common clinical intervention, leukapheresis, in the setting of hyperleukocytosis. It contrasts with the promising results seen with venetoclax plus intensive chemo in relapsed/refractory AML (63.79% ORR), which focused on treatment efficacy, whereas this analysis finds no clear mortality benefit for leukapheresis. It also complements earlier case-based insights, such as the diagnostic framework for Ph+ leukemia and the role of BCR::ABL1 testing, by emphasizing that supportive interventions like leukapheresis lack robust evidence. The findings highlight the gap between clinical practice and evidence, reinforcing the need for cautious interpretation of non-randomized data.

For people with acute myeloid leukemia (AML) and very high white blood cell counts, doctors sometimes use a treatment called leukapheresis. This procedure filters the blood to remove excess white blood cells. The goal is to prevent early complications and death.

A new meta-analysis combined data from 1406 adults with AML and hyperleukocytosis. It compared those who received leukapheresis with those who did not. The main question was whether leukapheresis reduced the chance of dying within 30 days.

The results showed no clear difference in 30-day death rates between the two groups. The chance of death was about the same whether or not patients had leukapheresis. However, the studies had serious limitations, and the overall evidence was very low quality.

One major issue is that sicker patients may have been more likely to receive leukapheresis, which can make the treatment look less effective. This is called confounding by indication. Because of this, we cannot be sure that leukapheresis does not help some patients.

In summary, current evidence does not prove that leukapheresis lowers early death risk in AML. More reliable studies are needed to know if this treatment is truly beneficial.

What this means for you:

Leukapheresis did not clearly reduce 30-day death in AML, but evidence is weak and more research is needed.

Common questions

What is leukapheresis?

Leukapheresis is a procedure that filters white blood cells out of the blood. It is sometimes used in people with acute myeloid leukemia (AML) who have very high white blood cell counts, called hyperleukocytosis, to quickly lower those counts.

Does leukapheresis lower the risk of dying within 30 days for AML patients?

In this meta-analysis, leukapheresis was not clearly associated with lower 30-day mortality compared with no leukapheresis. The odds ratio was 0.94 with a 95% confidence interval of 0.65 to 1.34, meaning no significant difference was found.

How strong is the evidence for leukapheresis in AML?

The evidence is very weak. The certainty of evidence was rated as very low, and most studies had a serious risk of bias. Also, confounding by indication is a major limitation, meaning sicker patients might be more likely to get leukapheresis, which can skew results.

Study Details

Study typeMeta analysis

Sample sizen = 1,406

EvidenceLevel 1

PublishedAug 2026

PMID42185077

View Original Abstract ↓

INTRODUCTION: Leukapheresis is used for rapid cytoreduction in adults with acute myeloid leukemia (AML) and hyperleukocytosis, but its effect on early mortality remains uncertain. We performed an updated systematic review and meta-analysis of comparative studies. METHODS: MEDLINE, CENTRAL, ClinicalTrials.gov, Google Scholar, and citation searching were searched from inception to March 2026. Comparative studies of leukapheresis versus no leukapheresis in adults with AML and hyperleukocytosis were included. Risk of bias was assessed using ROBINS-I, and certainty of evidence was assessed using GRADE. Random-effects meta-analysis of crude 2 × 2 data was performed using odds ratios (ORs). RESULTS: Thirteen retrospective comparative studies were included; 10 studies comprising 1,406 patients contributed to the primary 30-day mortality analysis. Leukapheresis was not clearly associated with lower 30-day mortality compared with no leukapheresis (OR 0.94, 95% CI 0.65-1.34; I = 0.0%). Only one study reported an adjusted estimate. Most studies were at serious risk of bias, and certainty of evidence was very low. CONCLUSIONS: Current non-randomized evidence does not establish a reliable early-mortality benefit of leukapheresis. Confounding 3by indication remains a major limitation. REGISTRATION: This study was prospectively registered on PROSPERO (identifier: CRD420261351743).

Leukapheresis not clearly linked to lower 30-day mortality in AML with hyperleukocytosisLeukapheresis Shows No Clear Early Death Benefit in AML

How this fits prior evidence

Common questions

Study Details

Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients

Your Blood May Signal a Deadly Clotting Crisis Before It Strikes

Clinical research that matters. Delivered to your inbox.

Leukapheresis not clearly linked to lower 30-day mortality in AML with hyperleukocytosisLeukapheresis Shows No Clear Early Death Benefit in AML

How this fits prior evidence

Common questions

More on Acute Myeloid Leukemia

Study Details

Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients

Your Blood May Signal a Deadly Clotting Crisis Before It Strikes

Clinical research that matters. Delivered to your inbox.

Related in Hematology

From Other Specialties